Paperback. Hypertension is a prevalent condition, especially in those over 50, and can lead to severe cardiovascular complications. Irbesartan, an angiotensin II receptor blocker (ARB), is commonly used to manage hypertension, but its low aqueous solubility (1 mg/ml) limits its bioavailability. This study aimed to improve Irbesartan's solubility through solid dispersions using carriers like b-cyclodextrin, HPMC K4M, PEG4000, and Gelatin. b-cyclodextrin showed the greatest enhancement in solubility, as confirmed by phase solubility studies. Characterization through DSC and SEM indicated the drug's transformation from crystalline to amorphous form, improving dissolution. FTIR studies confirmed no interaction between the drug and carriers. In vitro dissolution tests revealed that b-cyclodextrin (1:9) formulations significantly increased the dissolution rate compared to pure Irbesartan and other carriers. Thus, using b-cyclodextrin in solid dispersions effectively enhances Irbesartan's solubility and therapeutic potential in treating hypertension. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.

Codice articolo 9786208119713

Contatta il venditore

Segnala questo articolo

Dati bibliografici

Titolo: Enhancing Irbesartan Bioavailability via Solid Dispersion (Paperback)
Editore: LAP Lambert Academic Publishing
Data di pubblicazione: 2024
Lingua: Inglese
ISBN 10: 6208119715
ISBN 13: 9786208119713
Rilegatura: Paperback
Condizione: new

Descrizione articolo

Riassunto

Hypertension is a prevalent condition, especially in those over 50, and can lead to severe cardiovascular complications. Irbesartan, an angiotensin II receptor blocker (ARB), is commonly used to manage hypertension, but its low aqueous solubility (1 μg/ml) limits its bioavailability. This study aimed to improve Irbesartan’s solubility through solid dispersions using carriers like β-cyclodextrin, HPMC K4M, PEG4000, and Gelatin. β-cyclodextrin showed the greatest enhancement in solubility, as confirmed by phase solubility studies. Characterization through DSC and SEM indicated the drug’s transformation from crystalline to amorphous form, improving dissolution. FTIR studies confirmed no interaction between the drug and carriers. In vitro dissolution tests revealed that β-cyclodextrin (1:9) formulations significantly increased the dissolution rate compared to pure Irbesartan and other carriers. Thus, using β-cyclodextrin in solid dispersions effectively enhances Irbesartan’s solubility and therapeutic potential in treating hypertension.

Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.

Descrizione libreria

Visita la pagina della libreria

Informazioni sull?azienda del venditore

The Nile Group Pty Ltd
42 Apex Drive, Truganina, VIC, 3029, Australia

Condizioni di vendita e spedizione

Condizioni di vendita

We guarantee the condition of every book as it's described on the Abebooks web sites. If you're dissatisfied with your purchase (Incorrect Book/Not as Described/Damaged) or if the order hasn't arrived, you're eligible for a refund within 30 days of the estimated delivery date. If you've changed your mind about a book that you've ordered, please use the Ask bookseller a question link to contact us and we'll respond within 2 business days.

Condizioni di spedizione

Please note that titles are dispatched from our UK and NZ warehouse. Delivery times specified in shipping terms. Orders ship within 2 business days. Delivery to your door then takes 8-15 days.